Anteris Technologies

Anteris Technologies is a structural heart company founded in 2006 with the slogan "Anteris Technologies is a structural heart company focused on developing innovative & durable health solutions." This company is focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. Their DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime. The DurAVR™ THV is a unique, single-piece valve with a first-in-class biomimetic design that replicates the normal blood flow of a healthy human aortic valve. Anteris Technologies operates in the Biotechnology and Health Care industries and is headquartered in the United States. Their last investment was a $35.00M Post-IPO Equity investment on 09 February 2023, with investors including Perceptive Advisors and L1 Capital. The company is known by the ticker symbol $AVR on the ASX and is associated with hashtags such as DurAVR, ADAPT, structuralheart, TAVR, TAVI, and cardiology.